Out Of The Pipeline
Out Of The Pipeline
Doxepin for insomnia
Low-dose doxepin may relieve sleep maintenance insomnia and is not designated as a controlled substance
Out Of The Pipeline
Guanfacine extended release for ADHD
Once-daily formulation may improve adherence and control symptoms across a full day
Out Of The Pipeline
Asenapine for schizophrenia and bipolar I disorder
Receptor binding profile and sublingual delivery distinguish asenapine from other atypical antipsychotics
Out Of The Pipeline
Iloperidone for schizophrenia
New treatment option for patients who have not fully responded to or cannot tolerate other antipsychotics
Out Of The Pipeline
Transcranial magnetic stimulation for depression
FDA approves a new option for patients who fail 1 antidepressant trial
Out Of The Pipeline
Extended-release fluvoxamine for social anxiety disorder and OCD
New formulation allows once-daily dosing and might improve tolerability, reduce side effects.
Out Of The Pipeline
Desvenlafaxine for depression
New SNRI may have more predictable effects and a lower risk of drug-drug interactions.
Out Of The Pipeline
Transdermal rivastigmine for dementia
Transdermal formulation may reduce side effects, making optimal dosing easier.
Out Of The Pipeline
Risperidone’s 2 new pediatric indications
Approval supports antipsychotic use in children with schizophrenia or bipolar disorder.
Out Of The Pipeline
IM aripiprazole for acute agitation
Fast-acting injectable has shown efficacy 45 to 60 minutes after dosing in randomized, controlled studies.
Out Of The Pipeline
Lisdexamfetamine for ADHD
Extended-action psychostimulant offers daylong coverage and has comparatively low abuse potential.